Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel
Pp. 156-180 (25)
P.S. Bisen, Z. Khan, N. Khan and G.B.K.S. Prasad
Oxaliplatin, is a platinum-based antineoplastic agent used in cancer
chemotherapy and paclitaxel is one of several cytoskeletal drugs that target tubulin.
Paclitaxel-treated cells have defects in mitotic spindle assembly, chromosome
segregation, and cell division. Survivin is one of the key anti-apoptotic proteins which
is over-expressed in most of the human cancers; and is associated with their
biologically aggressive characteristics and drug resistance. Investigations presented
deals with the evaluation of the efficacy of oxaliplatin and paclitaxel combination as a
potential strategy in controlling HNSCC cell proliferation and the assessment of
correlation between occurrence of apoptosis and changes in expression of survivin
(IAP) by employing two HNSCC cell lines (Cal27 and NT8e) and one normal cell line
(293) panel with differential level of survivin expression in accordance with
chemosensitivity. The combined treatment of cells with paclitaxel and oxaliplatin
resulted in a significantly higher cytotoxicity compared to individual single drug
treatment. Cytotoxicity was prominent in paclitaxel to oxaliplatin (pacl-oxal) sequence
treatment with an approximate two-fold increase in apoptosis compared to oxaliplatin
to paclitaxel (oxal-pacl) sequence treatment.
Paclitaxel treatment also significantly increased survivin expression with reduced
apoptosis at low concentration. Oxaliplatin, when combined with paclitaxel, decreased
the survivin level with increased cell death. Study was further designed to explore the
effect(s) of survivin-inhibition by a small interfering RNA (siRNA therapy) method on
the apoptosis in HNSCC cells expressing increased sensitivity of the cancer cell lines to
paclitaxel whereas over-expression of survivin in the transfected 293-cell line provided
resistance. Survivin played a critical role in paclitaxel resistance through the
suppression of apoptosis, and a significant induction of apoptosis was observed when
oxaliplatin was combined with paclitaxel at least in part by the down-regulation of
survivin. In conclusion, the interaction between drugs was synergistic and scheduledependent.
Apoptosis, Chemotherapy, Cytotoxicity, HNSCC, Oxaliplatin,
School of Studies in Biotechnology, Jiwaji University, Gwalior 474011, India.